PDCD1 and melanoma: In melanoma or relapsed small cell lung cancer patients, combined blockade led to more severe grade 3-4 adverse events (54% to 55%) compared to solely anti-CTLA-4 (24% to 27%) or anti-PD-1 (15% to 16%) treatment (114–116).